| Entry |
|
|---|
| Name |
Givosiran (USAN/INN);
Givlaari (TN)
|
|---|
| Formula |
C524H694F16N173O316P43S6
|
|---|
| Exact mass |
16292.034
|
|---|
| Mol weight |
16300.3229
|
|---|
| Efficacy |
Accumulation reduction (neurotoxic intermediates) |
|---|
| Disease |
Acute hepatic porphyria [DS: H00202] |
|---|
| Comment |
RNA interference (RNAi) drug
Treatment of acute hepatic porphyria
|
|---|
| Target |
|
|---|
| Pathway |
| hsa00860 | Porphyrin and chlorophyll metabolism |
|
|---|
| Brite |
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Acyltransferases
ALAS1
D11702 Givosiran (USAN/INN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11702
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11702
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
